Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Unravelling the mystery of Barrett’s oesophagus October 25, 2021 GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... September 17, 2020 How Living in Service to Others Helped Me Cope During Cancer March 9, 2023 Study Shows Thymic Health is Linked to Cancer Patients’ Response to... October 16, 2025 Load more HOT NEWS Food for Thought: A Fresh Perspective on Nutrition Drug Combination May Have Potential for Cancers with TP53 Mutations Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed...
